Riskpilot← Back to searchSign inGet full accessCGS Life Science Consulting AB
ABActiveOrg 5591962526Apelgatan 3Public relations and communication activities · NACE 7330Est. 20190 employees
Revenue 2024
SEK 5K
-96% vs 2023
EBITDA margin
-1221.8%
-208% vs 2023
Equity ratio
97.6%
Financial strength
Net profit 2024
SEK -58K
-234% vs 2023
| Revenue | SEK 5K | -96% |
| EBITDA | SEK -59K | -208% |
| Net profit | SEK -58K | -234% |
| Total assets | SEK 1,1M | -7% |
| Equity | SEK 1,1M | -5% |
| Employees | 0 | — |
Legal name
CGS Life Science Consulting AB
Org number
5591962526
Legal form
Aktiebolag
NACE code
7330 · Public relations and communication activities
Founded
25 februari 2019
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget kommer att vara verksamt inom Life Science-sektorn i form av konsultverksamhet som läkemedelskonsulent, vetenskaplig rådgivare, fältproduktchef eller försäljningschef riktat till läkemedelsindustrin, diagnostikföretag eller medicintekniska företag. Bolaget kan åta sig uppdrag i egen regi eller som inhyrd underkonsult vilket som passar uppdragsgivaren bäst. I konsultens arbete riktat till läkemedelsindustrin ingår att kontakta hälso & sjukvårdspersonal i samförstånd och enligt LIF regelverk bla delge läkemedelsinformation, anordna utbildningsaktiviteter delta i specialistföreningars kongresser och vara allmänt behjälplig med information och frågeställningar rörande uppdragsgivarens produkter. Vad gäller konsularbete inom diagnostik/medicinteknisk utrustning ingår demonstrationer och utprovning av uppdragsgivarens produkter, utbildning och service av utrustning.
Address
Apelgatan 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 144 | 324 | 254 | 125 | 5 |
| Staff expenses | — | — | −39 | −24 | −20 |
| EBITDA | 981 | 242 | 155 | 55 | −59 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 981 | 242 | 155 | 55 | −59 |
| Net financials | — | −1 | −3 | −0 | 2 |
| Profit before tax | 981 | 241 | 152 | 55 | −58 |
| Tax | −226 | −50 | −32 | −12 | — |
| Net profit | 755 | 191 | 120 | 43 | −58 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 378 | 1 428 | 1 135 | 1 170 | 1 093 |
| Equity | 953 | 1 144 | 1 081 | 1 124 | 1 067 |
| Long-term debt | 2 | 8 | 0 | — | — |
| Short-term debt | 423 | 276 | 53 | 45 | 26 |
| Total debt | 425 | 284 | 53 | 45 | 26 |
EBITDA margin
-1221.8%
This company
15.8%
Market median
-7833% vs market
20202024
Equity ratio
97.6%
This company
38.2%
Market median
+155% vs market
20202024
Return on equity
-5.4%
This company
18.4%
Market median
-129% vs market
20202024
Net profit margin
-1188.5%
This company
8.1%
Market median
-14773% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CGS Life Science Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Marcus Levi Sällberg-Widh | Deputy Board Member | 0 companies |
| Karl Gunnar Sällberg | Board of Directors | 0 companies |